Work

Multicenter Retrospective Study of the Impact of Localized Therapy on Prognosis in Patients With Oligometastatic Solid Tumors

Year: 2026

Type: article

Abstract: BACKGROUND: Local therapy has recently been applied to treat oligometastatic cancer across various malignant cancers. However, definitive evidence for local treatment regimens remains lacking. We aimed to evaluate the clinical outcomes of combining local therapy with systemic treatment for patients with oligometastatic solid tumors including breast cancer, liver cancer, and non-small cell lung cancer (NSCLC) in a multicenter retrospective study. METHODS: From January 2013 to December 2023, 575 patients with fewer than or equal to five metastases of breast cancer, liver cancer, and NSCLC in three tertiary university hospitals were analyzed retrospectively. The primary endpoint was overall survival (OS). The secondary endpoints included progression-free survival (PFS) and prognostic factors affecting the treatment outcomes. RESULTS: Before propensity score matching, significant differences were observed in both OS and PFS between the local therapy plus systemic therapy and systemic therapy alone groups (p < 0.001 and p < 0.001). After PSM, PFS remained significantly different (p = 0.017), but OS did not (p = 0.076). In liver cancer, before PSM analysis showed a significant PFS benefit (p = 0.011), which was absent after PSM for both OS and PFS (p = 0.568 and p = 0.363). For both breast cancer and NSCLC patients, no significant differences in OS or PFS were found after PSM. CONCLUSIONS: Local treatment of solitary metastatic lesions showed that no statistically significant difference was observed in OS or PFS of patients with advanced oligometastatic breast, liver cancer, and NSCLC.

Source: Cancer Medicine

DOI: 10.1002/cam4.72280